// App-Quantinova.ai

1874 : Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial

Researchers

Presenter

  • Roland Chapurlat

Principal Investigators

  • Rogely Boyce

  • Jacques Brown

  • Stephane Horlait

  • Cesar Libanati

  • Yifei Shi

  • Rachel Wagman

  • Pascale Chavassieux

Medical Centers

  • Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway

  • INSERM UMR , Universite de Lyon, Lyon, France

  • Amgen Inc, Thousand Oaks, CA

  • CHU de Quebec and Laval University, Quebec, QC, Canada

  • Amgen Inc., Boulogne Billancourt, France

  • UCB Pharma, Brussels, Belgium

Locations

  • Norway

  • France

  • United States

  • Canada

  • Belgium

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Osteoporosis

Biomarkers

  • Bone Mineral Density

Drug/Treatment

  • Tetracycline

  • Romosozumab

  • Denosumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved